DE3688418D1 - Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. - Google Patents

Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Info

Publication number
DE3688418D1
DE3688418D1 DE8686901613T DE3688418T DE3688418D1 DE 3688418 D1 DE3688418 D1 DE 3688418D1 DE 8686901613 T DE8686901613 T DE 8686901613T DE 3688418 T DE3688418 T DE 3688418T DE 3688418 D1 DE3688418 D1 DE 3688418D1
Authority
DE
Germany
Prior art keywords
promotor
produced
human metallothionein
expression systems
desired protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686901613T
Other languages
English (en)
Other versions
DE3688418T2 (de
Inventor
Peter Kushner
Claire Cofer
Jeffrey FRIEDMAN
Karen Talmadge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Application granted granted Critical
Publication of DE3688418D1 publication Critical patent/DE3688418D1/de
Publication of DE3688418T2 publication Critical patent/DE3688418T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6486—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23015—Renin (3.4.23.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8686901613T 1985-02-13 1986-02-11 Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. Expired - Lifetime DE3688418T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70129685A 1985-02-13 1985-02-13
US80167485A 1985-11-25 1985-11-25
PCT/US1986/000296 WO1986004920A1 (en) 1985-02-13 1986-02-11 Human metallothionein-ii promoter in mammalian expression system

Publications (2)

Publication Number Publication Date
DE3688418D1 true DE3688418D1 (de) 1993-06-17
DE3688418T2 DE3688418T2 (de) 1993-08-26

Family

ID=27106764

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686901613T Expired - Lifetime DE3688418T2 (de) 1985-02-13 1986-02-11 Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Country Status (9)

Country Link
US (1) US5089397A (de)
EP (1) EP0217822B1 (de)
AT (1) ATE89314T1 (de)
AU (1) AU580145B2 (de)
CA (1) CA1338829C (de)
DE (1) DE3688418T2 (de)
DK (1) DK488386A (de)
ES (1) ES8707564A1 (de)
WO (1) WO1986004920A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
IL78314A0 (en) * 1985-04-03 1986-07-31 Biotechnology Res Ass Expression vectors and methods for the production of recombinant human renin
WO1987002037A1 (en) * 1985-09-26 1987-04-09 Genetics Institute, Inc. Pulmonary surfactant proteins
WO1987002062A1 (en) * 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
GB8629153D0 (en) * 1986-12-05 1987-01-14 Ciba Geigy Ag Hybrid proteins
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
WO1991012317A1 (en) * 1990-02-09 1991-08-22 Genentech, Inc. Lung cell line and methods of use
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
JP2524939B2 (ja) * 1991-12-03 1996-08-14 株式会社ニチレイ エンハンサ−及びその用途
US5342782A (en) * 1992-02-24 1994-08-30 Washington University Tightly regulated expression system for eucaryotic cells
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
WO1994026107A1 (en) * 1993-05-13 1994-11-24 New York University Psychosis protecting nucleic acid, peptides, compositions and method of use
JPH07163368A (ja) * 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えｄｎａとその組換えｄｎａを含む形質転換体
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
US6297027B1 (en) 1996-07-31 2001-10-02 Purina Mills, Inc. Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6277592B1 (en) 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
USRE40911E1 (en) 1998-04-22 2009-09-08 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2002068668A2 (en) * 2001-02-22 2002-09-06 Immunex Corporation Compositions and methods for production cell culture
WO2002095061A1 (en) * 2001-05-18 2002-11-28 New York University Methods of screening test substances for treating or preventing diseases involving an oxidative stress
PT2287288E (pt) 2002-07-09 2012-12-10 Baxter Int Meio isento de proteína animal para cultura de células
US20060177837A1 (en) * 2004-08-13 2006-08-10 Ivan Borozan Systems and methods for identifying diagnostic indicators
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006108455A1 (en) * 2004-11-02 2006-10-19 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
DK1907561T3 (da) * 2005-06-24 2013-12-02 Enteris Biopharma Inc Cellelinjer til ekspression af enzym, der er anvendeligt i fremstillingen af amiderede produkter
EP1974014B1 (de) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptid-freie zellkulturmedien
AU2008309934B2 (en) 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
EA037404B1 (ru) 2008-11-10 2021-03-24 Арбутус Биофарма Корпорэйшн Липиды и композиции для доставки лекарственных средств
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
NZ712719A (en) 2009-06-10 2017-03-31 Arbutus Biopharma Corp Improved lipid formulation
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
EP2575764B1 (de) 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen
EP2407534A1 (de) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Verfahren und Reagenzien zum Erhalt von transkriptionell aktiven virusähnlichen Artikeln und rekombinante Virionen
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
ES2721639T3 (es) 2010-10-06 2019-08-02 Inst Catalana Recerca Estudis Avancats Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3202760B1 (de) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylierte lipide und deren verwendung zur wirkstofffreisetzung
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 肺がん転移の診断、予後診断および処置のための方法
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2687852A1 (de) 2012-07-17 2014-01-22 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Diagnose und Behandlung des chronischen Erschöpfungssyndroms
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
KR20150122731A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 예후 및 치료 방법
CN105431548A (zh) 2013-03-15 2016-03-23 生物医学研究机构基金会 用于癌转移的诊断、预后和治疗的方法
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
KR101867134B1 (ko) * 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
JP7021245B2 (ja) 2017-03-10 2022-02-16 エフ．ホフマン－ラ ロシュ アーゲー 多重特異性抗体を生産するための方法
PT115073A (pt) 2018-10-09 2020-05-29 Inst De Biologia Molecular E Celular Ibmc Ácido nucleico para ativar a expressão e a produção de proteínas
EP4371569A1 (de) 2022-11-16 2024-05-22 Universidad del País Vasco/Euskal Herriko Unibertsitatea Vlps gegen akute myeloische leukämie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE72583T1 (de) * 1981-11-23 1992-02-15 University Patents Inc Steuerung der dna-sequenzen-transkription.
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
JPS60500358A (ja) * 1982-12-23 1985-03-22 アメリカ合衆国 マウスの細胞内で組み換えｄｎａによって生産されたヒト成長ホルモン
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin

Also Published As

Publication number Publication date
WO1986004920A1 (en) 1986-08-28
AU5513586A (en) 1986-09-10
AU580145B2 (en) 1989-01-05
ES8707564A1 (es) 1987-08-01
DE3688418T2 (de) 1993-08-26
EP0217822A1 (de) 1987-04-15
US5089397A (en) 1992-02-18
DK488386D0 (da) 1986-10-13
EP0217822B1 (de) 1993-05-12
EP0217822A4 (de) 1989-05-11
CA1338829C (en) 1997-01-07
ATE89314T1 (de) 1993-05-15
DK488386A (da) 1986-12-15
ES551913A0 (es) 1987-08-01

Similar Documents

Publication Publication Date Title
DE3688418D1 (de) Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
ES2080809T3 (es) Receptores de factor de necrosis tumoral alfa y beta.
IL94128A (en) Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE122004000009I1 (de) Methode zur Herstellung von menschlichen Wachstumshormonen.
CA1267497C (en) PROTEIN RECOVERY
FI875427A (fi) Menetelmä valmistaa hevosen -interferonia
AU600253B2 (en) Expression of eucaryotic proteins
DK573587A (da) Fremgangsmaade til fremstilling af en faktor viii (ahf)-holdig fraktion
DE3852777D1 (de) Verfahren zur Konstruktion einer animalen Zellinie für die Herstellung von humanem Interferon-beta.
EP0427863A4 (en) Dna coding for protein capable of combining with enhancer of alpha-fetoprotein gene
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
IL82207A0 (en) Production of peptides,recombinant plasmid used therefor and animal cells transformed therewith
ATE103983T1 (de) Licht-induzierbarer promotor.
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
SE8502430D0 (sv) A cdna molecule coding for the expression of an interferon alfa type polypeptide, a bacterial or cellular host transformed with such molecule and a polypeptide showing interferon activity prepared by such host
IL69747A (en) Nucleic acids,vectors comprising them,avian growth hormones encoded by the nucleic acids,and method of producing the hormones using such vectors
ATE80181T1 (de) Zur wirksamen gen-expression faehiger vektor und verwendung desselben.
AU8706191A (en) A dna encoding a protein which binds to the enhancer of alpha-fetoprotein gene
AU3330184A (en) Immune interferon and method for its purification
JPS6474988A (en) Synthetic gene of cystatin c, corresponding recombinant plasmid and recombinant